Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial
Bergenstal RM, Weinstock RS, Mathieu C, et al.
Lancet. Pub. online 10 Sep 2024.
Leggi
Liraglutide for children 6 to <12 years of age with obesity - a randomized trial
Fox CK, Barrientos-Pérez M, Bomberg EM, et al.
N Engl J Med. Pub. online 10 Sep 2024.
Leggi
The large language model GPT-4 compared to endocrinologist responses on initial choice of antidiabetic medication under conditions of clinical uncertainty
Flory JH, Ancker JS, Kim SYH, Kuperman G, et al.
Diabetes Care. Pub. online 9 Sep 2024.
Leggi
Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment
Wysham C, Bajaj HS, Del Prato S, et al.
N Engl J Med. Pub. online 10 Sep 2024.
Leggi
Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries
Li C, Bishop TRP, Imamura F, et al.
Lancet Diabetes Endocrinol. Pub. online 12 Sep 2024.
Leggi
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40 months’ follow-up
Mehrotra-Varma S, Lu JY, Boparai MS, et al.
Diabetes Obes Metab. Pub. online 2 Sep 2024.
Leggi
The use of composite endpoints in cardiovascular outcome trials for diabetes: a review of 22 randomized clinical trials published since 2008
Kafai Yahyavi S, Kristensen PL, Hjorthøj C, et al.
Diabetes Obes Metab. Pub. online 2 Sep 2024.
Leggi
Fracture risk revisited: Bone mineral density T-score and fracture risk in type 2 diabetes
Kafai Yahyavi S, Kristensen PL, Hjorthøj C, et al.
Diabetes Obes Metab. Pub. online 2 Sep 2024.
Leggi